An apparent increase of calmodulin (CaM) activity was previously observed in the heart and kidney but not in the liver of spontaneously-hypertensive rats (SHR) 
Introduction
Abnormalities of cellular calcium transport, binding, and sequestration, which may lead to alterations in free cytosolic calcium levels, have been noted in hypertension (1) (2) (3) (4) (5) (6) . Arterial smooth muscle cell tension and therefore peripheral vascular resistance appear to be controlled by variations in free cytosolic calcium levels (7) . Many studies have uncovered several anomalies of key Ca2"-dependent enzymes and cellular processes in hypertension including Ca2"-Mg2" ATPase (2, 8) , calmodulin (CaM)'-dependent ATPase (9) , and phospholipase 1. Abbreviations used in this paper: CaM, calmodulin; NM, normotensive, randomly bred mice; PDE, phosphodiesterase; SHM, spontaneously hypertensive mice; SHR, spontaneously hypertensive rats; TES, N-tris(hydroxymethyl) methyl-2-amino ethanesulfonic acid buffer; WKY, Wistar-Kyoto rats.
A2 (10) . The cellular hyperplasia seen in hypertension may also be related to changes in intracellular Ca2+ (1 1-13) . CaM is known to regulate smooth muscle tone by activation of myosin light-chain kinase or by binding caldesmon, a contractile inhibitory protein, resulting in actin-myosin interactions (14) (15) (16) . It therefore appears logical to postulate that Ca2+-dependent enzyme alterations could play an important role in hypertension.
CaM is a major intracellular Ca2`receptor that can control the activity of many key enzymes and cellular processes, including those just mentioned. In vitro, CaM has been shown to suppress differences in calcium binding and ATP-dependent accumulation between spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto rats (WKY) (17) . Its role in hypertension is, however, still not clear.
CaM content can be determined by direct RIA or by a radioenzymatic assay based on the activation ofCaM-deficient cyclic nucleotide phosphodiesterase (PDE) (18) . Using the latter assay, we have observed an apparent increase of CaM content in the heart and kidney but not in the liver of spontaneously hypertensive mice (SHM) (Schlager strain) and rats compared with their corresponding normotensive counterparts (19, 20) . However, with a direct RIA, Higaki et al. (21) reported a decrease of CaM levels in SHR organs compared with those from normotensive WKY.
In this study, we report the presence ofan activator ofCaM in the heart, kidney, and in cultured aortic smooth muscle cells from hypertensive animals with an apparent increase of activity in organs of hypertensive origin.
Methods
Animals. These experiments were performed on 10-wk-old SHM, SHR, and age-matched, normotensive, randomly bred mice (NM) and rats (WKY).
Preparation of tissue supernatants. The mice and the rats were killed by exsanguination under anesthesia. Their hearts and kidneys were quickly removed and frozen in liquid nitrogen. Each frozen organ was weighed and pulverized with a caulk Vari-Mix II-M for 10-20 s. The powders obtained were resuspended in 5 vol of 10 mM N-tris(hydroxymethyl) methyl-2-amino ethanesulfonic acid (TES) buffer (pH 7) containing 1 mM DTT, I mM EGTA, and 50,ug/ml leupeptin. These homogenates were heated at 00-100'C for 3 min, then cooled rapidly tensive mice were precipitated with ammonium sulfate into five fractions. Fraction 1 represented precipitated proteins obtained with 0-30% saturation of ammonium sulfate after centrifugation at 15 (Table I) . This parameter was not dependent on the protein concentration in normotensive tissues but it was in hypertensives, that is, CaM recovery increased linearly with the protein concentration in hypertensive supernatants (Fig. 3) . The addition of escalating amounts of supernatant, which included both the activator and endogenous CaM, resulted in an increasingly greater apparent CaM content (Fig. 4) Effect ofsupernatants from hypertensive and normotensive tissues on PDE activation curve by CaM. Fig. 5 shows that the hypertensive but not the normotensive sample modifies the standard curve of phosphodiesterase stimulation by CaM. At suboptimal concentrations of CaM, the hypertensive sample increased the PDE stimulation whereas it did not increase the maximal stimulation. The reciprocal transformation of these curves (Fig. 5, inset) demonstrated that the hypertensive sample decreases the concentration of CaM (from 1.1 to 0.4 ng) needed to reach 50% of the maximal stimulation of PDE. These results suggest that the activator present in hypertensive sample acts mainly by increasing the affinity of the PDE for CaM with no important effect on the maximal stimulation (from 2.9 to 2.6-fold stimulation). (500-fold dilution) of hypertensive and normotensive tissues. The activator was found in fractions 2 (pellet and floating precipitate) and 5 after dialysis against TES-DTT buffer, as indicated by increased CaM recovery. It was significantly more active in fraction 2 of the hypertensive than in the normotensive kidney. The presence of the activator in fraction 5 of the two strains was detectable only in undiluted samples compared with fraction 2, which necessitated a 50-fold dilution (Table III) .
Fractions 2 and 5 from SHM and NM revealed a displacement to the left of the standard curve of PDE stimulation by CaM and confirmed the greater effect of fractions from hypertensives (data not shown).
Fractions containing the activator could be heated at 1000C for 15 min with no effect on the CaM recovery.
Fraction 2 from SHM, which appeared to contain the highest levels of the activator, was further extracted with diethyl ether. Both the original fraction and its ether extract from hypertensives potentiated CaM stimulation of PDE, whereas the residual water phase showed no such effect (Fig.  6) . A similar observation was made with fraction 5 (data not shown). Using ammonium sulfate precipitation followed by ether extraction, we can obtain an enriched preparation ofthe activator deprived of endogenous CaM. This component seems to possess a lipidic character.
To further narrow down the identity of the endogenous activator of CaM, the total lipids were extracted (hexane/isopropanol; 3:2) either from whole SHM heart homogenate or from supernatant, and fractionated by silicic acid column chromatography into four fractions (neutral lipids and FFA, PGs, glycolipids, phospholipids). The effect of these purified lipid fractions (devoid of endogenous CaM) on the CaM stimulation of PDE was evaluated as described in Methods. In the whole homogenate, the phospholipid-and glycolipid-containing fractions were active whereas in the supernatant, the glycolipid-containing fraction showed the most significant activation of CaM in the assay of PDE stimulation. The potentiation of PDE stimulation by the glycolipid-containing fraction from supernatant was observed to be calcium and CaM dependent. Studies to identify the structure ofthe glycolipid or of the chromatographically identical lipid activator of CaM are presently being performed in our laboratory. CaMand calcium requirementsfor PDE stimulation by the partially purifed activator (ether extract). Fig. 7 shows the requirement of CaM and Ca2" for PDE stimulation by enriched fractions of the activator (ether extract). Basal PDE activity (100%) was determined in the absence of exogenous Ca2' and EGTA. The addition of EGTA slightly inhibited PDE due to contamination by trace amounts of Ca2' and CaM. The presence of either exogenous Ca2+ or EGTA only had a mild effect on PDE activity. The activator alone (ether extract) also had only a slight impact on the stimulation of PDE, which was increased considerably by the combination of CaM and the activator in the absence or presence of added calcium. The removal of contaminating calcium (which was high enough to allow a half maximal effect of CaM) by EGTA abolished the effect of the activator as well as that of CaM. Thus, the influence of the activator on PDE stimulation is dependent on the presence of both CaM and Ca2".
Discussion
As mentioned before, the major intracellular Ca2' receptor, CaM, regulates the activity of many enzymes and cellular processes including those altered in hypertension. Changes in calcium metabolism in hypertension have been studied by many groups. The cytosolic Ca2+ concentration, for example, has been found to be higher in hypertensives than in normotensives (4-6, 27, 28) . However, most of the investigations into abnormal enzyme function in hypertension were performed in broken cell systems where exogenous Ca2+ concentrations were added. Thus, the differences observed between hyperten- sives and normotensives could not be due to differences in intracellular Ca2" concentrations, which also applies to the present study. CaM content was reported to be unchanged or lower in hypertensive tissues (10, 21, 29) . Our initial results (19, 20) , however, showed an increase ofCaM activity (in contrast to its content) in the heart and kidney of SHR and SHM. In this report, we demonstrated that this is due to the presence of an activator of CaM in the heart and kidney of SHR and SHM and in aortic cells of SHR. The activator is also present but at lower concentrations in the hearts and kidneys of normotensive rats and mice. It can stimulate CaM in the presence of Ca2" and, consequently, CaM-dependent PDE activity. The stimulation of CaM-dependent PDE by the activator increases with the concentration of tissue and this is reflected by an enhanced recovery of CaM in hypertensive tissues. Thus, with very diluted tissue samples, the CaM recovery is close to 100% and the endogenous CaM content appears to be slightly lower in hypertensive than in normotensive tissues (Table II) . On the other hand, at higher tissue concentrations, the apparent CaM content is significantly higher in hypertensive tissues, presumably because of the interaction between calcium-CaM and the activator (Fig. 1) . The increase of CaM activity does not seem to be caused by alterations of CaM but rather by the elevation of its endogenous activator in hypertension.
We also observed an augmentation of this activator in cultured aortic smooth muscle cells derived from SHR. These experiments were performed on cells after the 1th passage, which suggests that the increase of the activator was a consequence ofa genetic abnormality and not a sequel ofa compensatory hypertension mechanism (20) .
The general mechanisms by which CaM regulates many enzymes have been reviewed in the literature (30) (31) (32) . The stimulation of PDE by the activator was Ca2" and CaM dependent. The activator appears to affect the affinity ofthe PDE for CaM rather then its maximal stimulation. Our investigation represents the first demonstration of an activator of CaM in organs and cultured cells that are implicated in the maintenance of hypertension in two different species that have a genetic type of hypertension in common.
Studies to identify this activator are presently being performed in our laboratory. The preliminary results reported here suggest that it is of a lipid nature. Several phospholipids have been demonstrated to activate cyclic nucleotide PDEs (33) but this stimulation is calcium and CaM independent. In addition, phospholipids are known to mimic the effect ofCaM on (Ca2`-Mg2`)-ATPase (34, 35) . It is relevant in the context of the present study to underline that the abnormalities of CaMdependent ATPase have been reported in hypertension (3, 9, 36, 37) . We should also mention that in these studies ATPase (found to be decreased in hypertension) was found in membrane fractions in which the cytosolic activator described here would have been removed. It is our imminent goal to ascertain the effect of the cytosolic activator on ATPase activity in hypertension. The phospholipid effects on CaM-dependent PDE reported by Wolff and Brostrom (33) in fact have also been observed to compete with those of CaM, which was not the case for the CaM activator described here.
It has been shown that the insulin-stimulated hydrolysis of a novel phosphatidylinositol-containing glycolipid generates a complex carbohydrate-phosphate substance containing inositol and glucosamine that may stimulate cAMP PDE (38) . This glycolipid can be distinguished from the one described herein since the potentiation of CaM-dependent PDE stimulation by the lipid fraction in our experiments is Ca2`and CaM dependent and does not appear to be dependent on its hydrolysis into active products. We thus have to first identify the activator of CaM-dependent PDE, which is increased in hypertension, to establish its mechanism of action as well as its putative role in the pathogenesis of hypertension.
